Merck closes license agreement for LM-299

Merck will record a pre-tax charge relating to the upfront payment of $588 million

India is the fourth largest medical devices market in Asia: Anupriya Patel

The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months

Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities

Genpharmasec enters into supper stockist agreement with Amneal Healthcare

Laurus Labs invests in Laurus Bio

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination

For people with relapsed or refractory diffuse large B-cell lymphoma